Alkermes plc. Proceeds from Long-Term Debt Issued
Alkermes plc. (ALKS) reported Proceeds from Long-Term Debt Issued of $23.57 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-21.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2024-02-21
- Alkermes plc. proceeds from issuance of long-term debt for the quarter ending 2021-12-31 was $0.00.
- Alkermes plc. proceeds from issuance of long-term debt for the quarter ending 2021-09-30 was $0.00.
- Alkermes plc. proceeds from issuance of long-term debt for the quarter ending 2021-06-30 was $0.00.
- Alkermes plc. proceeds from issuance of long-term debt for the quarter ending 2021-03-31 was $23.57M.
- Alkermes plc. proceeds from issuance of long-term debt for fiscal 2021 was $23.57M.
- Alkermes plc. proceeds from issuance of long-term debt for fiscal 2013 was $366.48M, a 17.48% decline from fiscal 2012.
- Alkermes plc. proceeds from issuance of long-term debt for fiscal 2012 was $444.10M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $0.00 derived: sum of 2 quarters · filed 2024-02-21 | $0.00 derived: sum of 3 quarters · filed 2024-02-21 | $23.57M 10-K · filed 2024-02-21 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $23.57M 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $23.57M 10-Q · filed 2022-07-27 | ||
| 2021-03-31 | $23.57M 10-Q · filed 2022-04-27 | |||
| 2013-03-31 | -$2.07M 10-Q · filed 2014-04-30 | -$2.07M derived: sum of 2 quarters · filed 2014-04-30 | $366.48M 10-K · filed 2015-02-24 | |
| 2012-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-01-31 | $368.56M 10-Q · filed 2013-01-31 | ||
| 2012-09-30 | $368.56M 10-Q · filed 2013-10-31 | |||
| 2012-03-31 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | $0.00 derived: sum of 2 quarters · filed 2014-02-27 | $444.10M 10-KT · filed 2014-02-27 | |
| 2011-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-01-31 | $444.10M 10-Q · filed 2013-01-31 | ||
| 2011-09-30 | $444.10M 10-Q · filed 2012-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |